The deep and durable efficacy data, including activity after prior approved CAR-T, are encouraging for CB-011's differentiation. Watch for the dose expansion data in H2 2026, which will further inform the registrational path. The company's ability to fund a pivotal Phase 3 is a key risk given its ~$178M market cap.
Price Chart
Executive Summary
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. In the BCMA-naïve recommended dose expansion cohort (n=12), results showed a 92% ORR, 83% CR/≥CR rate, 91% MRD negativity, and 50% of patients sustaining ≥CR at 15 months, with a manageable safety profile. These data will be presented at EHA on June 14, 2026, and initial dose expansion data in both BCMA-naïve and BCMA-exposed patients are expected in H2 2026.
Key Facts
- Single dose of CB-011 at the 450M cell RDE produced 92% ORR, 83% CR/≥CR rate, 91% MRD negativity in BCMA-naïve patients (n=12).
- 50% of patients in the BCMA-naïve RDE cohort maintained ≥CR at 15 months; median follow-up 17.7 months.
- A case study of a patient who had failed approved autologous CAR-T (cilta-cel) achieved CR by day 28 with CB-011.
- Safety profile was manageable with no GvHD, parkinsonism, or cranial nerve palsies; one (8%) ≥Gr 3 CRS, no ≥Gr 3 ICANS at RDE.
- EHA oral presentation scheduled for June 14, 2026; initial dose expansion data expected in H2 2026.
- CB-011 has FDA RMAT, Fast Track, and Orphan Drug designations for r/r multiple myeloma.
Financial Impact
No financial figures were disclosed. These are clinical data only.
Risk Factors
- CaMMouflage Phase 1 is still ongoing with a small dataset (n=48 total); larger expansion cohorts may show different results.
- CB-011 faces competition from approved BCMA CAR-Ts and other allogeneic approaches; commercial adoption is uncertain.
- Caribou's limited financial resources and history of operating losses could constrain further development and pivotal trial funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310377 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | 8-K | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 11, 2026 16w ago | Press Release | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 5, 2026 16w ago | DEFA14A | $1.84 $1.83 | ▼ −0.54% | ▼ −2.17% | $1.23 (−33.42%) |
Apr 24, 2026 22w ago | DEFA14A | $2.13 $2.16 | ▲ +1.41% | ▼ −3.55% | $1.23 (−42.49%) |
Mar 5, 2026 30w ago | 8-K | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Mar 5, 2026 30w ago | Press Release | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Feb 28, 2026 30w ago | Institutional Cluster | $1.84 $1.72 | ▼ −6.52% | ▲ +1.42% | $1.23 (−33.42%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access